Ligand Pharmaceuticals Incorporated filed its Form 10-Q for the quarterly period ended September 30, 2026, disclosing condensed consolidated financial statements and management discussion as of and for that period.

Key Highlights

  • Total assets reached $2.237 billion as of September 30, 2026, up from $1.561 billion at December 31, 2025, according to the filing.
  • Cash and cash equivalents declined to $55.958 million from $174.927 million at year-end 2025, while short-term investments stood at $391.437 million.
  • Long-term financial royalty assets, net, grew to $772.619 million from $196.877 million at December 31, 2025, reflecting the company's expanded royalty portfolio.
  • XOMA was acquired on July 14, 2026, with goodwill rising to $207.860 million from $101.541 million at December 31, 2025, in connection with the transaction.
  • Current portion of convertible senior notes, net, was $448.308 million at September 30, 2026, compared to zero at December 31, 2025, with a noncurrent portion of $679.909 million.
  • Shares of common stock outstanding totaled 20,002,986 as of October 27, 2026, per the filing.
  • Total liabilities increased to $1.276 billion from $543.425 million at December 31, 2025.

Ligand's Balance Sheet Expands Following XOMA Acquisition and Royalty Portfolio Growth

According to the 10-Q filing with the SEC, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) reported a significant expansion of its balance sheet for the period ended September 30, 2026. Total assets grew to $2.237 billion from $1.561 billion at December 31, 2025, driven largely by increases in goodwill, intangible assets, and long-term financial royalty assets. The company disclosed that XOMA Royalty Holdings Corporation, described in the filing as "a Nevada corporation, and its wholly owned subsidiaries," was acquired on July 14, 2026, which the filing identifies as a contributor to the increase in goodwill, from $101.541 million to $207.860 million.

The filing reported that long-term financial royalty assets, net, rose sharply to $772.619 million from $196.877 million at the prior year-end, reflecting growth in the royalty asset portfolio. Intangible assets, net, also increased to $302.039 million from $225.438 million. Offsetting some asset growth, the company's cash and cash equivalents fell to $55.958 million from $174.927 million, while short-term investments decreased to $391.437 million from $558.594 million. The filing also noted the appearance of current and noncurrent restricted cash balances of $4.112 million and $43.321 million, respectively, which were zero at December 31, 2025.

On the liabilities side, the filing disclosed that total liabilities more than doubled, reaching $1.276 billion from $543.425 million at year-end 2025. A key driver was the reclassification of $448.308 million of convertible senior notes, net, to current liabilities, while the noncurrent portion stood at $679.909 million. Long-term contingent liabilities also increased substantially, to $34.072 million from $2.934 million. The filing noted 20,002,986 shares of common stock outstanding as of October 27, 2026, and identified Ligand as a large accelerated filer. Forward-looking statements contained in the filing are the company's own and are subject to its cautionary language regarding risks and uncertainties.

What Was Disclosed

Ligand Pharmaceuticals filed its quarterly 10-Q for the period ended September 30, 2026, disclosing condensed consolidated balance sheet data, including the impact of the July 14, 2026 XOMA acquisition, expanded royalty assets, and changes in convertible note classifications and cash balances.